Endo, Teva OxyContin Generics Approved By FDA; Launch Dates Uncertain
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies' risk management programs will feature labeling, education, monitoring and intervention elements "consistent with" Purdue's program for the opioid.